<DOC>
	<DOC>NCT02169544</DOC>
	<brief_summary>The purpose of this study is to evaluate the risk of infections and malignancies among Rheumatoid Arthritis (RA) patients treated with Abatacept compared to other RA treatments.</brief_summary>
	<brief_title>Post-marketing Study Assessing the Long-Term Safety of Abatacept</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Patient has at least two claims for RA (714.xx) in the 180 days prior to and including the index date (baseline period) Patient is aged 18 years or older on the index date Patient was enrolled in the database for at least 180 days before the index date Patient is newly prescribed Abatacept or another RA treatment and has at least two claims for the treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>